Filing Flows › Onconetix (ONCO) › Q2 2026 › vs Q2 2025
Onconetix (ONCO) Q2 2026 vs Q2 2025 (year over year)
Onconetix's revenue fell $89K (-84%) from $106K in Q2 2025 to $17K in Q2 2026.
Onconetix, Q2 2026: revenue $17K (-84% year over year), net loss $2.9M, operating cash flow −$1.9M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $17K | $106K | −$89K | -84% |
| Net loss | $2.9M | $2.4M | $495K | +21% |
| Costs & expenses | $2.9M | $2.5M | $405K | +16% |
| Operating costs | $2.7M | $2.0M | $706K | +35% |
| Interest & other, net | $137K | $437K | −$301K | -69% |
| Cost of revenue | $13K | $36K | −$23K | -64% |
| SG&A | $2.2M | $1.5M | $722K | +47% |
| Other operating costs | $489K | $482K | $7K | +1% |
| Operating cash sources | $2.9M | $2.4M | $495K | +21% |
| Depreciation & amortization | $3K | $4K | −$1K | -29% |
| Share-based compensation | $7K | $31K | −$24K | -76% |
| Working capital & other | $939K | $927K | $12K | +1% |
| Cash used in operations | $1.9M | $1.4M | $508K | +36% |
| Net loss absorbed | $2.9M | $2.4M | $495K | +21% |
Questions
How much did Onconetix's revenue grow year over year in Q2 2026?
Onconetix's revenue fell $89K (-84%) from $106K in Q2 2025 to $17K in Q2 2026.